58 results
8-K
EX-99.1
SRZN
Surrozen Inc
8 May 24
Surrozen Provides First Quarter 2024 Financial Results and Business Update
4:12pm
in healthy volunteers and chronic liver disease patients in February 2024
Regulatory filings submitted in multiple countries for Phase 1b study … with chronic liver disease and healthy volunteers. SZN-043 demonstrated acceptable safety and tolerability in all subjects, with evidence of
target
8-K
EX-99.2
SRZN
Surrozen Inc
1 Apr 24
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
8:52am
Healthy VolunteersChronic Liver Dx SAH SAH N 36 18 - 30 ~300 Design SAD/MADPlacebo-controlled SAD/MADOpen-label, SOC Controlled TBD Countries New
8-K
EX-99.1
SRZN
Surrozen Inc
1 Apr 24
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
8:52am
for severe liver diseases, initially focusing on alcohol-associated hepatitis. The Company has completed a Phase 1a clinical trial in patients with chronic
424B3
SRZN
Surrozen Inc
22 Jan 24
Prospectus supplement
5:24pm
1a clinical trial in patients with chronic liver disease and healthy volunteers is complete. Surrozen expects to release safety and pharmacodynamic
8-K
7nz6sbce
18 Jan 24
Other Events
8:41am
424B3
xf3i6h mbp5xuf
8 Nov 23
Prospectus supplement
4:27pm
8-K
EX-99.1
rxmvmm37b1h8vnz
8 Nov 23
Surrozen Provides Third Quarter 2023 Financial Results
4:09pm
424B3
x9ks86cf4j6
9 Aug 23
Prospectus supplement
4:39pm
8-K
EX-99.1
qez id9k9bnj5
9 Aug 23
Surrozen Provides Second Quarter 2023 Financial Results
4:16pm
424B3
5bwx0barpnxi38gm8rx
10 May 23
Prospectus supplement
4:47pm
8-K
EX-99.1
i0c7btt3
10 May 23
Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates
4:14pm
424B3
bxofs7new qkfa9
7 Apr 23
Prospectus supplement
5:20pm
424B3
0698phzg8 3up
6 Apr 23
Prospectus supplement
5:15pm
POS AM
mf0qdt y0l5cq0c5sbt
31 Mar 23
Prospectus update (post-effective amendment)
4:52pm
POS AM
fm0zm pw4ejfrmcuz06r
31 Mar 23
Prospectus update (post-effective amendment)
9:09am